drugset / Trial / NCT07377526
TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
Phase 1/2
Recruiting
37 enrolled
M.D. Anderson Cancer Center
United States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and metastatic pancreatic cancer. The primary objectives are to assess safety and determine the recommended Phase II dose (RP2D).
Timeline
- Start
- 2026-05-26
- Primary completion
- 2028-03-01
- Completion
- 2030-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGFBR2 KO CAR27/IL-15 NK cells | Cell therapy | — | Intravenous |